Gabapentin is authorised to treat epilepsy and peripheral neuropathic pain, or nerve pain. The known side effects of gabapentin are outlined in the product information, the Summary of Product Characteristics (SPC) for healthcare professionals, and the Patient Information Leaflet which is provided in each pack of the medicine.

The SPC states that in the treatment of peripheral neuropathic pain, such as painful diabetic neuropathy and post-herpetic neuralgia, efficacy and safety have not been examined in clinical studies for treatment periods longer than five months. If a patient requires the medication for longer than five months to treat peripheral neuropathic pain, the treating physician should assess the patient's clinical status and determine the need for additional therapy. Epilepsy normally requires long-term treatment and the SPC states that the dosage for gabapentin should be determined by the treating physician according to the clinical response and side effects experienced by the individual patient.

The product information for gabapentin lists amnesia as a common side effect and mental impairment as an uncommon side effect. Dementia is not a known side effect of gabapentin.

Gabapentin can cause drug dependence, and the product information includes warnings that patients treated with gabapentin should be monitored for symptoms of misuse, abuse, or dependence. After discontinuation of short- and long-term treatment with gabapentin, withdrawal symptoms have been observed, and gabapentin should be discontinued gradually over a minimum of one week.

As with all medicines, the safety of gabapentin is kept under continual review by the Medicines and Healthcare products Regulatory Agency using a number of data sources including reports of suspected side effects through the Yellow Card Scheme, data from marketing authorisation holders, and research published in the scientific literature.

Gabapentin is authorised to treat epilepsy and peripheral neuropathic pain, or nerve pain. The known side effects of gabapentin are outlined in the product information, the Summary of Product Characteristics (SPC) for healthcare professionals, and the Patient Information Leaflet which is provided in each pack of the medicine.

The SPC states that in the treatment of peripheral neuropathic pain, such as painful diabetic neuropathy and post-herpetic neuralgia, efficacy and safety have not been examined in clinical studies for treatment periods longer than five months. If a patient requires the medication for longer than five months to treat peripheral neuropathic pain, the treating physician should assess the patient's clinical status and determine the need for additional therapy. Epilepsy normally requires long-term treatment and the SPC states that the dosage for gabapentin should be determined by the treating physician according to the clinical response and side effects experienced by the individual patient.

The product information for gabapentin lists amnesia as a common side effect and mental impairment as an uncommon side effect. Dementia is not a known side effect of gabapentin.

Gabapentin can cause drug dependence, and the product information includes warnings that patients treated with gabapentin should be monitored for symptoms of misuse, abuse, or dependence. After discontinuation of short- and long-term treatment with gabapentin, withdrawal symptoms have been observed, and gabapentin should be discontinued gradually over a minimum of one week.

As with all medicines, the safety of gabapentin is kept under continual review by the Medicines and Healthcare products Regulatory Agency using a number of data sources including reports of suspected side effects through the Yellow Card Scheme, data from marketing authorisation holders, and research published in the scientific literature.

Gabapentin is authorised to treat epilepsy and peripheral neuropathic pain, or nerve pain. The known side effects of gabapentin are outlined in the product information, the Summary of Product Characteristics (SPC) for healthcare professionals, and the Patient Information Leaflet which is provided in each pack of the medicine.

The SPC states that in the treatment of peripheral neuropathic pain, such as painful diabetic neuropathy and post-herpetic neuralgia, efficacy and safety have not been examined in clinical studies for treatment periods longer than five months. If a patient requires the medication for longer than five months to treat peripheral neuropathic pain, the treating physician should assess the patient's clinical status and determine the need for additional therapy. Epilepsy normally requires long-term treatment and the SPC states that the dosage for gabapentin should be determined by the treating physician according to the clinical response and side effects experienced by the individual patient.

The product information for gabapentin lists amnesia as a common side effect and mental impairment as an uncommon side effect. Dementia is not a known side effect of gabapentin.

Gabapentin can cause drug dependence, and the product information includes warnings that patients treated with gabapentin should be monitored for symptoms of misuse, abuse, or dependence. After discontinuation of short- and long-term treatment with gabapentin, withdrawal symptoms have been observed, and gabapentin should be discontinued gradually over a minimum of one week.

As with all medicines, the safety of gabapentin is kept under continual review by the Medicines and Healthcare products Regulatory Agency using a number of data sources including reports of suspected side effects through the Yellow Card Scheme, data from marketing authorisation holders, and research published in the scientific literature.

Gabapentin is authorised to treat epilepsy and peripheral neuropathic pain, or nerve pain. The known side effects of gabapentin are outlined in the product information, the Summary of Product Characteristics (SPC) for healthcare professionals, and the Patient Information Leaflet which is provided in each pack of the medicine.

The SPC states that in the treatment of peripheral neuropathic pain, such as painful diabetic neuropathy and post-herpetic neuralgia, efficacy and safety have not been examined in clinical studies for treatment periods longer than five months. If a patient requires the medication for longer than five months to treat peripheral neuropathic pain, the treating physician should assess the patient's clinical status and determine the need for additional therapy. Epilepsy normally requires long-term treatment and the SPC states that the dosage for gabapentin should be determined by the treating physician according to the clinical response and side effects experienced by the individual patient.

The product information for gabapentin lists amnesia as a common side effect and mental impairment as an uncommon side effect. Dementia is not a known side effect of gabapentin.

Gabapentin can cause drug dependence, and the product information includes warnings that patients treated with gabapentin should be monitored for symptoms of misuse, abuse, or dependence. After discontinuation of short- and long-term treatment with gabapentin, withdrawal symptoms have been observed, and gabapentin should be discontinued gradually over a minimum of one week.

As with all medicines, the safety of gabapentin is kept under continual review by the Medicines and Healthcare products Regulatory Agency using a number of data sources including reports of suspected side effects through the Yellow Card Scheme, data from marketing authorisation holders, and research published in the scientific literature.

The NHSBSA holds patient identifiable information for the number of items dispensed and claimed for reimbursement. The following table shows the total number of prescription items for clonazepam and other benzodiazepines, z-drugs, antidepressants, opioids, pregabalin, and gabapentin drug groups, as well as the percentage and number of unique identified patients for those drug groups for 2024/25:

Notes:

1. for the clonazepam and other benzodiazepines drug groups, the figures represent patients who have received any combination of clonazepam and/or other benzodiazepines, as no patient is counted twice within this row, even where multiple medications have been received; and
2. for the pregabalin, and gabapentin drug groups, please note these figures refer to the combined category of gabapentinoids.

Patient count totals included in the table should not be aggregated.

The Medicines and Healthcare Products Regulatory Agency (MHRA) is an executive agency of the Department and regulates medicine, medical devices, and blood components for transfusion in the United Kingdom, with responsibility for ensuring medicines meet appropriate standards of safety, quality, and efficacy. Medicines are authorised on the basis that the benefits exceed the risks, and all products are licensed by the MHRA before being placed on the market.

Product information for gabapentin currently carries warnings of potential side effects of confusion, mental impairment, amnesia, and anxiety, and therefore patients should be advised to exercise caution until they are familiar with the potential effects of the medicinal product. All new safety information continues to be carefully considered, and regulatory action will be taken if considered necessary.

All medicines have side effects, although not everyone will experience them. The MHRA encourages anyone who suspects or experiences a side effect of their medicine to report it to the MHRA through the Yellow Card scheme.

The following table shows the number of items dispensed and claimed for reimbursement for each of the categories requested, covering the most recently published 12-month period and the 12 months prior:

Source: NHS Business Services Authority.

In addition, the following table shows the patient identifiable information for the number of items dispensed and claimed for reimbursement for each of the categories requested, for the most recently published 12-month period and the 12 months prior:

Source: NHS Business Services Authority.

Notes:

1. for clonazepam and other benzodiazepines, this is the number of unique patients who have received any combination of clonazepam and/or other benzodiazepines, and no patient is counted twice even where multiple medications have been received;
2. the figures for pregabalin and gabapentin refer to the combined category of gabapentinoids; and
3. the data in this answer in both tables on opioids, is not directly comparable to data from the previous Parliamentary Questions, PQ137238 and PQ137239, referenced in the question, as these tables refer to opioids in general, while the previous Parliamentary Questions referred to opioid analgesics only.

The following table shows the number of items dispensed and claimed for reimbursement for each of the categories requested, covering the most recently published 12-month period and the 12 months prior:

Source: NHS Business Services Authority.

In addition, the following table shows the patient identifiable information for the number of items dispensed and claimed for reimbursement for each of the categories requested, for the most recently published 12-month period and the 12 months prior:

Source: NHS Business Services Authority.

Notes:

1. for clonazepam and other benzodiazepines, this is the number of unique patients who have received any combination of clonazepam and/or other benzodiazepines, and no patient is counted twice even where multiple medications have been received;
2. the figures for pregabalin and gabapentin refer to the combined category of gabapentinoids; and
3. the data in this answer in both tables on opioids, is not directly comparable to data from the previous Parliamentary Questions, PQ137238 and PQ137239, referenced in the question, as these tables refer to opioids in general, while the previous Parliamentary Questions referred to opioid analgesics only.

Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.

The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.

While we have no specific plans to do so, we are committed to expanding and transforming mental health services in England through the NHS Long Term Plan, so that more people, including those experiencing side effects from taking gabapentin, can get the mental health help and support that they need.

The information requested is attached.

Prescribing information is not held at local authority level so primary care trust data is provided for 2010-11 to 2012-13 and clinical commissioning group data for 2013-14. It is not possible to provide the full five years requested as data is only held for the latest 60 months.

There are currently some shortages of some strengths of gabapentin in the United Kingdom. However, we understand that stocks are generally available and that manufacturers have further deliveries due this week.